Table 1.
Baseline Characteristics and Clinical Data of Study Subjects
| Variable | neo-adjuvant surgery group(n = 28) | Isolated surgery group(n = 26) | P-value |
|---|---|---|---|
| Male gender | 82.1% | 84.6% | 0.999 |
| Age, yr | 62.63 ± 7.50 | 61.22 ± 6.26 | 0.437 |
| Site of tumor: | 0.890 | ||
| Stomach | 60.7% | 57.7% | |
| Lower esophagus | 21.4% | 19.1% | |
| Esophagogastric junction | 17.9% | 23.1% | |
| WHO performance status: | 0.779 | ||
| 0 | 67.9% | 65.4% | |
| 1 | 32.1% | 34.6% | |
| Size of tumor (T staging) | 0.434 | ||
| 1 | 3.6% | 0.0% | |
| 2 | 17.9% | 19.2% | |
| 3 | 39.3% | 50.0% | |
| 4 | 39.3% | 30.8% | |
| Lymph node involvement: | 0.789 | ||
| 0 | 7.1% | 7.7% | |
| 1 | 64.3% | 53.8% | |
| 2 | 28.6% | 38.5% |